1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Plevin, M.J.
Zhang, J.
Guo, C.
Roeder, R.G.
Ikura, M.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Proc.Natl.Acad.Sci.USA
PNASA6
0040
0027-8424
103
10242
10247
10.1073/pnas.0603463103
16803958
The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via a paired amphipathic helix-like TBP-associated factor homology domain
2006
10.2210/pdb2h7b/pdb
pdb_00002h7b
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1
SINGLE WAVELENGTH
M
1
1.0
11887.721
Core-binding factor, ML1-ETO
residues 83-185,
C169A
1
man
polymer
runt domain, alpha subunit 2, translocated to 1, cyclin D-related
no
no
GSARQLSKLKRFLTTLQQFGNDISPEIGERVRTLVLGLVNSTLTIEEFHSKLQEATNFPLRPFVIPFLKANLPLLQRELL
HAARLAKQNPAQYLAQHEQLLLDAS
GSARQLSKLKRFLTTLQQFGNDISPEIGERVRTLVLGLVNSTLTIEEFHSKLQEATNFPLRPFVIPFLKANLPLLQRELL
HAARLAKQNPAQYLAQHEQLLLDAS
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
Escherichia
sample
ETO
9606
Homo sapiens
562
Escherichia coli
BL21(DE3) Rosetta
plasmid
pGEX-4T-1
database_2
pdbx_struct_assembly
pdbx_struct_oper_list
struct_ref_seq_dif
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
1
0
2006-07-11
1
1
2008-05-01
1
2
2011-07-13
1
3
2021-10-20
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_struct_ref_seq_dif.details
RCSB
Y
RCSB
2006-06-01
REL
REL
This entry is the solution conformation of eTAFH bound to 17 residue AD1 peptide from human HEB. Structure of the bound AD1 peptide was not determined due to chemical exchange broadening of resonances from this molecule
target function
100
20
NOESY
4D_13C/15N-separated_NOESY
70 mM
6
AMBIENT
25
K
torsion angle dynamics
1
lowest energy
0.7 mM eTAFH U-15N, 13C, 20 mM sodium phosphate, pH 6.0, 50 mM NaCl, 1mM PMSF, 1mM AEBSF, 0.25 mM sodium azide, 90% H2O, 10% D2O
90% H2O/10% D2O
GUNTERT, P. ET AL.
refinement
CYANA
GUNTERT, P. ET AL.
structure solution
CYANA
500
Varian
UNITYPLUS
600
Varian
UNITYPLUS
800
Varian
UNITYPLUS
GLY
-1
n
1
GLY
-1
A
SER
0
n
2
SER
0
A
ALA
1
n
3
ALA
1
A
ARG
2
n
4
ARG
2
A
GLN
3
n
5
GLN
3
A
LEU
4
n
6
LEU
4
A
SER
5
n
7
SER
5
A
LYS
6
n
8
LYS
6
A
LEU
7
n
9
LEU
7
A
LYS
8
n
10
LYS
8
A
ARG
9
n
11
ARG
9
A
PHE
10
n
12
PHE
10
A
LEU
11
n
13
LEU
11
A
THR
12
n
14
THR
12
A
THR
13
n
15
THR
13
A
LEU
14
n
16
LEU
14
A
GLN
15
n
17
GLN
15
A
GLN
16
n
18
GLN
16
A
PHE
17
n
19
PHE
17
A
GLY
18
n
20
GLY
18
A
ASN
19
n
21
ASN
19
A
ASP
20
n
22
ASP
20
A
ILE
21
n
23
ILE
21
A
SER
22
n
24
SER
22
A
PRO
23
n
25
PRO
23
A
GLU
24
n
26
GLU
24
A
ILE
25
n
27
ILE
25
A
GLY
26
n
28
GLY
26
A
GLU
27
n
29
GLU
27
A
ARG
28
n
30
ARG
28
A
VAL
29
n
31
VAL
29
A
ARG
30
n
32
ARG
30
A
THR
31
n
33
THR
31
A
LEU
32
n
34
LEU
32
A
VAL
33
n
35
VAL
33
A
LEU
34
n
36
LEU
34
A
GLY
35
n
37
GLY
35
A
LEU
36
n
38
LEU
36
A
VAL
37
n
39
VAL
37
A
ASN
38
n
40
ASN
38
A
SER
39
n
41
SER
39
A
THR
40
n
42
THR
40
A
LEU
41
n
43
LEU
41
A
THR
42
n
44
THR
42
A
ILE
43
n
45
ILE
43
A
GLU
44
n
46
GLU
44
A
GLU
45
n
47
GLU
45
A
PHE
46
n
48
PHE
46
A
HIS
47
n
49
HIS
47
A
SER
48
n
50
SER
48
A
LYS
49
n
51
LYS
49
A
LEU
50
n
52
LEU
50
A
GLN
51
n
53
GLN
51
A
GLU
52
n
54
GLU
52
A
ALA
53
n
55
ALA
53
A
THR
54
n
56
THR
54
A
ASN
55
n
57
ASN
55
A
PHE
56
n
58
PHE
56
A
PRO
57
n
59
PRO
57
A
LEU
58
n
60
LEU
58
A
ARG
59
n
61
ARG
59
A
PRO
60
n
62
PRO
60
A
PHE
61
n
63
PHE
61
A
VAL
62
n
64
VAL
62
A
ILE
63
n
65
ILE
63
A
PRO
64
n
66
PRO
64
A
PHE
65
n
67
PHE
65
A
LEU
66
n
68
LEU
66
A
LYS
67
n
69
LYS
67
A
ALA
68
n
70
ALA
68
A
ASN
69
n
71
ASN
69
A
LEU
70
n
72
LEU
70
A
PRO
71
n
73
PRO
71
A
LEU
72
n
74
LEU
72
A
LEU
73
n
75
LEU
73
A
GLN
74
n
76
GLN
74
A
ARG
75
n
77
ARG
75
A
GLU
76
n
78
GLU
76
A
LEU
77
n
79
LEU
77
A
LEU
78
n
80
LEU
78
A
HIS
79
n
81
HIS
79
A
ALA
80
n
82
ALA
80
A
ALA
81
n
83
ALA
81
A
ARG
82
n
84
ARG
82
A
LEU
83
n
85
LEU
83
A
ALA
84
n
86
ALA
84
A
LYS
85
n
87
LYS
85
A
GLN
86
n
88
GLN
86
A
ASN
87
n
89
ASN
87
A
PRO
88
n
90
PRO
88
A
ALA
89
n
91
ALA
89
A
GLN
90
n
92
GLN
90
A
TYR
91
n
93
TYR
91
A
LEU
92
n
94
LEU
92
A
ALA
93
n
95
ALA
93
A
GLN
94
n
96
GLN
94
A
HIS
95
n
97
HIS
95
A
GLU
96
n
98
GLU
96
A
GLN
97
n
99
GLN
97
A
LEU
98
n
100
LEU
98
A
LEU
99
n
101
LEU
99
A
LEU
100
n
102
LEU
100
A
ASP
101
n
103
ASP
101
A
ALA
102
n
104
ALA
102
A
SER
103
n
105
SER
103
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
ALA
1
-93.37
-67.27
1
A
SER
22
173.08
163.52
1
A
GLU
24
-51.48
-75.80
1
A
VAL
33
-49.14
-73.18
1
A
SER
48
-75.50
-72.24
1
A
ASN
55
-57.81
-176.72
1
A
PHE
56
59.95
167.40
1
A
PHE
61
63.54
78.53
1
A
PHE
65
-70.35
-73.05
1
A
LEU
98
-90.88
50.62
1
A
LEU
99
-113.87
-74.60
2
A
ALA
1
-94.60
-72.95
2
A
VAL
33
-50.09
-71.26
2
A
LEU
58
179.92
126.79
2
A
PHE
61
57.08
80.29
2
A
ARG
82
-51.84
-70.61
2
A
LEU
100
-51.84
-71.04
3
A
SER
0
-117.44
54.38
3
A
ALA
1
-93.21
-60.98
3
A
VAL
33
-49.66
-71.82
3
A
SER
48
-73.57
-72.27
3
A
VAL
62
-97.19
-63.55
3
A
PHE
65
-66.13
-70.30
3
A
LEU
98
-92.07
53.90
3
A
ASP
101
-64.65
94.05
4
A
VAL
33
-50.47
-73.95
4
A
THR
54
-48.29
-75.24
4
A
ASN
55
-154.07
-62.75
4
A
PHE
56
179.82
-59.84
4
A
PHE
61
65.48
78.00
4
A
LEU
99
-56.17
100.86
4
A
ASP
101
-68.72
86.37
5
A
SER
0
-179.36
-166.42
5
A
ALA
1
-67.41
-72.21
5
A
SER
22
176.87
163.15
5
A
GLU
24
-53.72
-72.67
5
A
VAL
33
-50.61
-71.48
5
A
PRO
57
-69.75
-177.57
5
A
LEU
58
-59.01
108.30
5
A
VAL
62
-95.58
-60.29
5
A
LEU
98
-109.59
53.65
5
A
ASP
101
-65.09
97.95
5
A
ALA
102
-109.91
-62.97
6
A
SER
0
-113.08
55.96
6
A
ALA
1
-93.45
-61.03
6
A
SER
22
178.96
160.24
6
A
GLU
24
-53.45
-76.73
6
A
VAL
33
-51.25
-72.53
6
A
PHE
65
-61.02
-72.64
6
A
ASP
101
-65.42
91.59
7
A
SER
22
179.58
161.06
7
A
GLU
24
-52.78
-77.13
7
A
VAL
33
-48.80
-70.83
7
A
THR
54
-55.43
-177.80
7
A
ASN
55
-39.47
-70.11
7
A
PHE
56
179.41
-59.59
7
A
PHE
61
64.34
77.69
7
A
VAL
62
-95.27
-61.30
7
A
ALA
102
-61.09
-75.00
8
A
VAL
33
-49.96
-71.42
8
A
THR
54
-71.12
-75.09
8
A
PRO
57
-69.75
99.39
8
A
LEU
98
-101.56
77.04
8
A
LEU
100
-98.08
-66.69
9
A
SER
22
178.85
160.18
9
A
GLU
24
-53.53
-77.94
9
A
VAL
33
-49.95
-72.30
9
A
ASN
55
-54.37
176.48
9
A
PHE
61
52.10
80.25
9
A
GLU
96
-90.20
-64.06
9
A
LEU
98
-94.87
41.72
9
A
LEU
100
-138.24
-60.01
10
A
SER
0
-119.67
62.13
10
A
ALA
1
-93.35
-61.19
10
A
SER
22
178.09
160.61
10
A
VAL
33
-49.42
-71.87
10
A
SER
48
-69.75
-72.50
10
A
ASN
55
-60.54
-168.32
10
A
PHE
56
57.06
169.72
10
A
LEU
58
-38.24
136.82
10
A
PRO
60
-69.71
-87.60
10
A
LEU
99
-65.94
-170.78
10
A
LEU
100
-68.41
86.16
10
A
ASP
101
-96.58
30.24
10
A
ALA
102
-54.33
-70.07
11
A
ALA
1
-94.38
-72.20
11
A
SER
22
174.73
162.32
11
A
VAL
33
-49.66
-70.35
11
A
LEU
58
-45.98
106.50
11
A
VAL
62
-98.28
-61.53
11
A
ASP
101
-63.74
93.43
12
A
SER
0
-117.16
53.31
12
A
GLU
24
-52.83
-70.60
12
A
VAL
33
-49.58
-71.19
12
A
ASN
55
-53.53
176.49
12
A
PHE
56
61.46
163.71
12
A
LEU
58
-177.67
133.66
12
A
PHE
61
-103.99
79.46
12
A
VAL
62
-99.32
-67.48
12
A
LEU
99
-60.91
-168.82
12
A
ALA
102
-58.57
178.23
13
A
ALA
1
-93.90
-65.54
13
A
SER
22
178.98
159.45
13
A
GLU
24
-53.13
-77.02
13
A
VAL
33
-50.90
-73.59
13
A
PHE
56
63.30
162.03
13
A
PRO
57
-69.78
-168.39
13
A
PHE
65
-66.26
-73.43
13
A
LEU
99
-109.21
76.11
14
A
SER
0
-97.82
31.50
14
A
ALA
1
-90.71
-67.79
14
A
SER
22
179.14
159.97
14
A
GLU
24
-53.53
-77.57
14
A
THR
54
-51.19
170.54
14
A
PHE
56
179.78
-60.01
14
A
PRO
57
-69.74
85.95
14
A
PRO
60
-69.74
-86.74
14
A
LEU
99
-59.66
-175.02
14
A
LEU
100
-65.83
88.20
15
A
SER
0
-111.55
51.75
15
A
SER
22
178.76
161.70
15
A
VAL
33
-49.91
-73.11
15
A
ASN
55
-60.80
-177.20
15
A
PHE
56
60.68
163.86
15
A
PHE
61
50.67
81.70
15
A
VAL
62
-97.09
-62.29
15
A
PHE
65
-66.99
-71.30
15
A
LEU
98
-107.05
54.41
15
A
LEU
99
-56.75
-175.54
16
A
SER
0
-101.48
60.71
16
A
ALA
1
-93.63
-63.77
16
A
SER
22
178.06
160.63
16
A
VAL
33
-49.47
-71.58
16
A
THR
54
-68.58
-83.08
16
A
ASN
55
172.67
161.07
16
A
PHE
56
60.72
167.64
16
A
LEU
58
-29.70
133.57
17
A
SER
0
-179.39
-166.21
17
A
ALA
1
-67.18
-70.31
17
A
SER
22
178.59
161.15
17
A
VAL
33
-49.98
-71.42
17
A
PHE
56
63.78
168.36
17
A
LYS
85
31.01
49.55
17
A
LEU
99
-69.50
-73.57
18
A
SER
0
-111.05
64.25
18
A
ALA
1
-93.87
-64.38
18
A
SER
22
169.36
156.98
18
A
GLU
24
-53.39
-70.38
18
A
SER
48
-58.60
-72.29
18
A
ASN
55
-54.86
177.64
18
A
PHE
56
60.68
163.82
18
A
PHE
61
61.36
77.82
18
A
VAL
62
-95.99
-61.13
19
A
SER
0
-107.85
71.78
19
A
ALA
1
-94.37
-71.80
19
A
GLU
24
-54.49
-75.83
19
A
VAL
33
-50.90
-71.45
19
A
ASP
101
-93.51
47.62
20
A
ALA
1
-91.39
-63.56
20
A
SER
22
175.19
161.53
20
A
VAL
33
-50.35
-72.43
20
A
ASN
55
-56.56
-178.55
20
A
PHE
56
61.16
162.98
20
A
LEU
58
-175.04
131.67
20
A
PHE
61
58.48
78.34
20
A
VAL
62
-95.76
-65.22
20
A
LEU
100
-130.99
-52.49
Solution structure of the eTAFH domain from the human leukemia-associated fusion protein AML1-ETO
1
N
N
A
ALA
1
A
ALA
3
HELX_P
A
LEU
4
A
LEU
6
5
1
4
A
SER
5
A
SER
7
HELX_P
A
PHE
17
A
PHE
19
1
2
13
A
PHE
17
A
PHE
19
HELX_P
A
SER
22
A
SER
24
1
3
6
A
SER
22
A
SER
24
HELX_P
A
ASN
38
A
ASN
40
1
4
17
A
THR
42
A
THR
44
HELX_P
A
THR
54
A
THR
56
1
5
13
A
VAL
62
A
VAL
64
HELX_P
A
ALA
68
A
ALA
70
1
6
7
A
ASN
69
A
ASN
71
HELX_P
A
ALA
81
A
ALA
83
1
7
13
A
ARG
82
A
ARG
84
HELX_P
A
ALA
84
A
ALA
86
5
8
3
A
ALA
89
A
ALA
91
HELX_P
A
GLN
94
A
GLN
96
1
9
6
TRANSCRIPTION
4 HELIX BUNDLE, TRANSCRIPTION
Q7Z4J5_HUMAN
UNP
1
83
Q7Z4J5
ARQLSKLKRFLTTLQQFGNDISPEIGERVRTLVLGLVNSTLTIEEFHSKLQEATNFPLRPFVIPFLKANLPLLQRELLHC
ARLAKQNPAQYLAQHEQLLLDAS
83
185
2H7B
1
103
Q7Z4J5
A
1
3
105
1
cloning artifact
GLY
-1
2H7B
A
Q7Z4J5
UNP
1
1
cloning artifact
SER
0
2H7B
A
Q7Z4J5
UNP
2
1
CYS
engineered mutation
ALA
80
2H7B
A
Q7Z4J5
UNP
162
82
1
P 1